Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 266 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR “Mi corazón siempre dolerá”: Cómo honro a mi mejor amiga de... April 26, 2022 Lessons from the green: How sports psychology helped a top golf... March 16, 2023 Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 Breast Cancer Survivor Earned Yoga Instructor Certification During Chemo. Now She... May 8, 2019 Load more HOT NEWS Determination of the Incidence of Driver Mutations in Patients with NSCLC... Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation... Cuando necesita ayuda con responsabilidades de cuidado Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in...
